December 09, 2024

Cetuximab vs Durvalumab in Treatment of Head and Neck Cancers

Durvalumab, an immune checkpoint inhibitor, has shown activity in treating a wide range of cancers and has been proposed as a potentially safer and more effective option than cetuximab, according to L...

The ASCO Post

December 09, 2024

Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma

Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-200...

The ASCO Post

December 02, 2024

Radiotherapy With Durvalumab or Cetuximab in Locoregionally Advanced Head and Neck Cancer With Contraindication for Cisplatin

Could immune checkpoint inhibition be an option for patients with locoregionally advanced head and neck squamous cell carcinoma who are unable to take cisplatin? A phase II/III study investigated.

The ASCO Post

March 12, 2024

HPV-Associated Oropharyngeal Cancer: Intratreatment FDG-PET Response as a Biomarker for De-escalation of Radiotherapy

The use of imaging midtreatment for HPV-associated oropharyngeal squamous cell carcinoma may guide the use of deintensified chemoradiotherapy, according to a phase II study presented at the 2024 Multi...

The ASCO Post

September 14, 2023

Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer

Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head an...

The ASCO Post

March 05, 2024

HPV-Associated Oropharyngeal Cancer: Adjuvant Treatment Deintensification

Postoperative adjuvant therapy—both chemoradiotherapy and radiotherapy alone—for HPV-associated oropharyngeal squamous cell carcinoma may be safely de-escalated, according to results presented at the ...

The ASCO Post

September 14, 2023

Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer

In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (IMRT) was associated with improved patient-reported swallowi...

The ASCO Post

September 14, 2023

Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer

De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Resu...

The ASCO Post

February 28, 2024

Risk of Stroke in Survivors of Head and Neck Cancer

A study from Singapore evaluated the risk of stroke among survivors of head and neck cancer compared with the general population.

The ASCO Post